Reprogramming Immunity

Overcoming cancer immune resistance through microbiome derived technology

Reprogramming Immunity

Overcoming cancer immune resistance through microbiome derived technology

Featured in Science Magazine

Featured in Science Magazine

The Establishment of Ella Therapeutics

Ella Therapeutics was established as a spinoff from breakthrough research performed at the Ella Lemelbaum Institute for Immuno-oncology and Melanoma at Sheba Medical Center, ranked as one of the top ten hospitals in the world by Newsweek.

Our Mission and Unique Advantage

Our mission is to overcome cancer resistance to immune checkpoint inhibitors through alteration of the gut microbiome. We generate our proprietary data through human clinical testing accompanied by rigorous science and believe this differentiating strategy provides a unique advantage.

Our Platform

Immuno-therapy and microbiome​

Convergence of therapeutics with discovery

Our Platform

Immuno-therapy and microbiome​

Convergence of therapeutics with discovery

1

Alteration of Microbiome

2

Alteration of Immune Response

3

Clinical
Response

1

Alteration of Immune Response

2

Alteration of Immune Response

3

Clinical
Response